Skip to main content
. 2020 Apr 20;98(5):751–760. doi: 10.1007/s00109-020-01907-w

Fig. 2.

Fig. 2

Signaling lipid mediators (oxylipins) in control group and ocular MMP patients. a Oxylipins-LOX pathway. b Oxylipins-CYP450 pathway. c Oxylipins-ROS pathway. The intensity represents the relative quantitation of each metabolite